| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT04739813 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT04739813 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With… |
Enrollment reduced: 55 -> 34 participants |
| 2026-06-02 | NCT04739813 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With… |
date change Primary completion moved earlier: 2026-06-18 -> 2026-05-07 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07638722 Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating… | Phase 2 | Not Yet Recruiting |
| 2026-06-10 | NCT07638787 Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL | Phase 1/2 | Not Yet Recruiting |
| 2026-05-19 | NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06047080 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab… | Large B-Cell Lymphoma | Active, Not Recruiting |
| NCT05171647 | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab… | Non-Hodgkin Lymphoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT05260957 | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed… | Refractory Non-Hodgkin Lymphoma | Recruiting |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory… | Diffuse Large B-Cell Lymphoma | Recruiting |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | Diffuse Large B-Cell Lymphoma (DLBCL) | Recruiting |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse… | Lymphoma | Recruiting |
| NCT05615636 | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients… | Hodgkin Lymphoma | Recruiting |
| NCT05283720 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC)… | Non-Hodgkin Lymphoma | Recruiting |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting |
| NCT06890884 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide… | Lymphoma, Large B-Cell, Diffuse | Recruiting |
| NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse… | Diffuse Large B Cell Lymphoma | Not Yet Recruiting |
| NCT05798156 | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With… | Lymphoma, Large B-Cell, Diffuse | Active, Not Recruiting |
| NCT06594939 | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly… | Diffuse Large B Cell Lymphoma (DLBCL) | Not Yet Recruiting |
| NCT07594899 | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | Large B-Cell Lymphoma (LBCL) | Not Yet Recruiting |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating… | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell… | B-cell Lymphoma | Recruiting |
| NCT06040320 | Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant… | Post-transplant Lymphoproliferative Disorder | Recruiting |
| NCT07415980 | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in… | Double Expressor DLBCL | Not Yet Recruiting |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in… | Non-Hodgkins Lymphoma | Active, Not Recruiting |
| NCT07638787 | Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL | Large B-cell Lymphoma | Not Yet Recruiting |
| Phase 1 | |||
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the… | Aggressive Non-Hodgkin Lymphoma | Recruiting |
| NCT06015880 | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and… | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recruiting |
| NCT06730542 | Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With… | CNS Lymphoma | Recruiting |
| NCT04884035 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to… | Lymphoma, B-Cell | Recruiting |